R
RefleXion Medical
By leveraging positron emission tomography (PET), the gold standard in cancer imaging and staging in a novel way, RefleXion’s patented technology* causes tumors to continuously signal their location…
About RefleXion Medical
RefleXion Medical is a pioneering company in the field of radiotherapy, focusing on advanced cancer treatment. The company has developed a breakthrough technology known as Biology-Guided Radiotherapy (BgRT), which uses signals emitted from cancer cells to guide high doses of radiation directly to tumors, even while they are in motion. This approach aims to maximize the impact on the tumor while minimizing damage to surrounding healthy tissue. RefleXion's technology is particularly significant for patients with stage four cancer, who are often not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. By enabling the simultaneous treatment of multiple tumors in a single session, RefleXion is redefining the possibilities of radiotherapy. The company collaborates with other therapies such as chemotherapy, immunotherapy, and targeted drugs to provide a comprehensive treatment plan tailored to individual patient needs. RefleXion operates in the healthcare and medical technology market, serving oncology centers and hospitals. Its business model revolves around the sale and maintenance of its radiotherapy machines, as well as partnerships with pharmaceutical companies. Revenue is generated through the sale of equipment, service contracts, and collaborative agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 157
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Oncology, Radiology, Core AI, Spinout, Tech for Hospitals and Clinics, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2023 | $105M | $550M | Venrock · Ally Bridge Group · Pfizer Ventures · Catalio Capital Management | ↗ |
| DEBTDebt | Jul 2022 | $125M | — | Oxford Finance | ↗ |
Growth signals
Latest recorded traffic for RefleXion Medical is 9.5K monthly website visits, down 3.1% over the last three months. RefleXion Medical's team declined 16% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
RefleXion Medical in the Hayward ecosystem
The RefleXion Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Venrock
Pfizer
Sofinnova Partners
Johnson & Johnson Innovation
KCK
Series B and later14 investors entered at this stage
Johnson & Johnson
The Rise Fund (TPG)
GT Healthcare
T. Rowe Price
Oxford Finance
PSP Investments- PVPfizer Ventures
Ally Bridge Group
Sixty Degree Capital
Ascension Ventures
Hillenbrand
Catalio Capital Management
Pictet- SCSquarepoint Capital
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RefleXion Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RefleXion Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








